A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
Eligible age
18–65 yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
Sponsor: Eli Lilly and Company
You may qualify if…
- ✓ Participants must be 21 in Singapore.
- ✓ Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent (%) body weight change.
- ✓ Part A, B, D, and E
- ✓ Have a body mass index (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:
- ✓ hypertension
- ✓ dyslipidemia
- ✓ obstructive sleep apnea, or
- ✓ prediabetes.
You may not qualify if…
- ✕ Have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine (except for T2D in Part C), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
Where it's recruiting
Rogers
Anaheim · Los Alamitos · Walnut Creek
Daytona Beach · Miami · Winter Park
Columbus · Decatur
Springfield
Marlton
Columbus
Dallas · San Antonio
Source: ClinicalTrials.gov · NCT07881887 · last updated 2026-11-18